Overview

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate
Tofacitinib